KR950031068A - 골다공증의 복합 치료 - Google Patents

골다공증의 복합 치료 Download PDF

Info

Publication number
KR950031068A
KR950031068A KR1019950001289A KR19950001289A KR950031068A KR 950031068 A KR950031068 A KR 950031068A KR 1019950001289 A KR1019950001289 A KR 1019950001289A KR 19950001289 A KR19950001289 A KR 19950001289A KR 950031068 A KR950031068 A KR 950031068A
Authority
KR
South Korea
Prior art keywords
compound
alkoxy
formula
pharmaceutically acceptable
substituted
Prior art date
Application number
KR1019950001289A
Other languages
English (en)
Inventor
존 블랙 래리
조셉 쿨리난 죠지
Original Assignee
피터 지. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 지. 스트링거
Publication of KR950031068A publication Critical patent/KR950031068A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

본 발명은 1) 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물을; 2) 메드록시 프로게스테론, 노르에틴드론 또는 노르에티노드렐 중에서 선택된 프로게스틴 또는 그의 약학적으로 허용가능한 염과 함께; 상기 복합물을 유지시키거나 또는 골 밀도를 증가시키는 양으로 투여함을 포함하는 신규한 골다공증의 치료방번을 제공한다:
상기 식에서 R 및 R1은 독립적으로 수소, 하이드록실, C1-C6알콕시, C1-C6아실옥시, C1-C6알콕시-C2-C6아실옥시, R2-치환된 아릴옥시, R2-치환된 아로일옥시, R3-치환된 카보닐 옥시 또는 할로이고; R2는 C1-C6알킬, C1-C6알콕시, 수소 또는 할로이고; R3는 C1-C6알콕시 또는 아릴옥시이고; n은 2, 3 또는 4이고, p는 4, 5 또는 6이다.
본 발명은 또한 1) 일반식 (Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용해화물; 및 2) 메드록시 프로게스테론, 노르에틴드론 또는 노르에티노드렐중에서 선택된 프로게스틴 또는 그의 약학적으로 허용가능한 염을; 하나이상의 약학적으로 허용가능한 담체와 함께 상기 복합물이 골 손실을 억제시키는 양으로 포함하는, 골 손실 억제를 위한 약학 조성물을 제공한다.

Description

골다공증의 복합 치료
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 골 밀도의 유지 또는 증가, 또는 골 손실의 억제를 위해 복합적으로 사용하기 위한, 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염 또는 용매화물, 및 메드록시프로게스테론, 노르에틴드론 또는 노르에티노드렐중에서 선택된 프로게스틴 또는 그의 약학적으로 허용가능한 염:
    상기 식에서 R 및 R1은 독립적으로 수소, 하이드록실, C1-C6알콕시,C1-C6아실옥시, C1-C6알콕시-C2-C6아실옥시, R2-치환된 아릴옥시, R2-치환된 아로일옥시, R3-치환된 카보닐옥시 또는 할로이고; R2는 C1-C6알킬, C1-C6알콕시, 수소 또는 할로이고; R3는 C1-C6알콕시 또는 아릴옥시이고; n은 2, 3 또는 4이고, p는 4, 5 또는 6이다.
  2. 제1항에 있어서, 일반식(Ⅰ) 화합물이, R 및 R1이 하이드록실, C1-C6아릴옥시, C1-C6알콕시-C2-C6아릴옥시, R2-치환된 아로일옥시, 또는 R3-치환된 카보닐옥시인 화합물이고; 선택된 프로게스틴이 노르에틴드론 또는 노르에티노드렐인 화합물.
  3. 제2항에 있어서, 일반식 (Ⅰ)화합물이, R 및 R1이 하이드록실이고, n이2고, p가 4 또는 5인 화합물이고; 선택된 프로게스틴이 노르에틴드론인 화합물.
  4. 제3항에 있어서, 일반식( I )화합물이, p가 5인 화합물인 화합물.
  5. 제2항에 있어서, 일반식( I )화합물이, R 및 R1이 하이드록실이고, n이 2이고, p가 5인 화합물이고; 선택된 프로게스틴이 노르에티노드렐인 화합물.
  6. 제1항에 있어서, 상기 일반식( I )화합물의 투여량이 0.1 내지 약 1000mg/체중kg이고, 상기 선택된 프로게스틴의 투여량이 약 0.01 내지 약 500mg/체중kg인 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950001289A 1994-01-28 1995-01-25 골다공증의 복합 치료 KR950031068A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/189,399 1994-01-28
US08/189,399 US5591753A (en) 1994-01-28 1994-01-28 Combination treatment for osteoporosis

Publications (1)

Publication Number Publication Date
KR950031068A true KR950031068A (ko) 1995-12-18

Family

ID=22697178

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950001289A KR950031068A (ko) 1994-01-28 1995-01-25 골다공증의 복합 치료

Country Status (17)

Country Link
US (2) US5591753A (ko)
EP (1) EP0665015A3 (ko)
JP (1) JPH07267858A (ko)
KR (1) KR950031068A (ko)
CN (1) CN1084617C (ko)
AU (1) AU692811B2 (ko)
CA (1) CA2140952A1 (ko)
CZ (1) CZ290045B6 (ko)
HU (1) HUT72633A (ko)
IL (1) IL112455A (ko)
NO (1) NO950275L (ko)
NZ (1) NZ270386A (ko)
PH (1) PH31553A (ko)
RU (1) RU2181048C2 (ko)
TW (1) TW401296B (ko)
UA (1) UA29451C2 (ko)
ZA (1) ZA95556B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
WO1998048806A1 (en) * 1997-04-25 1998-11-05 Eli Lilly And Company Indene compounds having activity as serms
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
WO1999054325A1 (fr) * 1998-04-17 1999-10-28 Senga Pharmaceutical Laboratory Inc. Derives 1-heteroindene et compositions medicinales a base de tels derives
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
PL367094A1 (en) 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
ZA87332B (en) * 1986-02-27 1987-08-26 Warner Lambert Co Compositions containing fixed combinations
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
WO1993011074A1 (en) * 1991-11-25 1993-06-10 Healthguard, Incorporated Multistage coaxial encapsulated filter assembly
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss

Also Published As

Publication number Publication date
NO950275L (no) 1995-07-31
CN1084617C (zh) 2002-05-15
IL112455A0 (en) 1995-03-30
US5591753A (en) 1997-01-07
RU2181048C2 (ru) 2002-04-10
ZA95556B (en) 1996-07-24
EP0665015A2 (en) 1995-08-02
PH31553A (en) 1998-11-03
IL112455A (en) 1999-12-31
TW401296B (en) 2000-08-11
CN1111511A (zh) 1995-11-15
US5646137A (en) 1997-07-08
CZ17695A3 (en) 1995-10-18
NO950275D0 (no) 1995-01-25
AU1139095A (en) 1995-08-10
EP0665015A3 (en) 1998-04-08
AU692811B2 (en) 1998-06-18
CZ290045B6 (cs) 2002-05-15
CA2140952A1 (en) 1995-07-29
NZ270386A (en) 1996-09-25
HUT72633A (en) 1996-05-28
UA29451C2 (uk) 2000-11-15
JPH07267858A (ja) 1995-10-17
HU9500229D0 (en) 1995-03-28

Similar Documents

Publication Publication Date Title
KR950031068A (ko) 골다공증의 복합 치료
KR900011772A (ko) 3-(1,2,5,6-테트라하이드로피리딜)피롤로피리딘
KR970074765A (ko) 비타민 d₃ 동족체
KR960030938A (ko) 나프틸 화합물, 중간체, 조성물 및 방법
KR920700200A (ko) 19-노르-비타민 d 화합물
KR950016732A (ko) 피부 및 질의 위축 억제방법
RU98115774A (ru) Новые производные 19-нор-прегнена
KR920003968A (ko) 염증성 장 질환의 치료방법
KR950010893A (ko) 자궁내막증 억제 방법
KR950016723A (ko) 자가면역 질병의 억제 방법
KR950010892A (ko) 자궁 섬유증 억제 방법
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
KR890003691A (ko) 피페리딘 유도체 및 그를 함유하는 부정맥을 위한 치료예방제
KR950010894A (ko) 자궁 섬유증의 억제 방법
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
KR950016747A (ko) 여성의 임신 억제방법
KR910004191A (ko) 신질환치료제
KR890014107A (ko) 백금 화학 요법약제
KR940021064A (ko) 프레그네인 유도체의 사용 방법
KR970706825A (ko) 헬리코박터의 감염에 기인하는 질환의 치료제(remedy for diseases caused by infection with helicobacter)
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)
KR910011820A (ko) Ltb4 합성 저해제

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee